Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Therapeutics Report H2 2016 - Pipeline Review of 33 Companies & 55 Molecules - Research and Markets

Research and Markets
Posted on: 17 Oct 16

Research and Markets has announced the addition of the "Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016" report to their offering.

Programmed Cell Death Protein 1 pipeline Target constitutes close to 55 molecules. Out of which approximately 52 molecules are developed by Companies and remaining by the Universities Institutes.

Programmed Cell Death Protein 1 - Pipeline Review, H2 2016, outlays comprehensive information on the Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Programmed cell death protein 1 also known as PD-1 and CD279 is a protein that encoded by the PDCD1 gene. PD-1 is a cell surface receptor that belongs to the immunoglobulin superfamily and is expressed on T cells and pro-B cells. PD-1 functioning as an immune checkpoint plays an important role in down regulating the immune system by preventing the activation of T-cells, which in turn reduces autoimmunity and promotes self-tolerance.

The inhibitory effect of PD-1 is accomplished through a dual mechanism of promoting apoptosis (programmed cell death) in antigen specific T-cells in lymph nodes while simultaneously reducing apoptosis in regulatory T cells (suppressor T cells). The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 4, 7, 1, 25, 11 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Furthermore, this report also reviews key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Programmed Cell Death Protein 1 Overview
  3. Therapeutics Development
  4. Pipeline Products for Programmed Cell Death Protein 1 - Overview
  5. Pipeline Products for Programmed Cell Death Protein 1 - Comparative Analysis
  6. Programmed Cell Death Protein 1 - Therapeutics under Development by Companies
  7. Programmed Cell Death Protein 1 - Therapeutics under Investigation by Universities/Institutes
  8. Programmed Cell Death Protein 1 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Programmed Cell Death Protein 1 - Products under Development by Companies
  13. Programmed Cell Death Protein 1 - Products under Investigation by Universities/Institutes
  14. Programmed Cell Death Protein 1 - Companies Involved in Therapeutics Development
  • Aduro BioTech, Inc.
  • Agenus, Inc.
  • Aurigene Discovery Technologies Limited
  • BeiGene, Ltd.
  • Beijing Hanmi Pharmaceutical Co., Ltd.
  • BIOCAD
  • Cellular Biomedicine Group, Inc.
  • CytomX Therapeutics, Inc.
  • Eli Lilly and Company
  • Enumeral Biomedical Holdings, Inc.
  • Immunovo BV
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Jounce Therapeutics, Inc.
  • Les Laboratoires Servier SAS
  • MacroGenics, Inc.
  • MD Biosciences GmbH
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Molecular Partners AG
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • PharmaEssentia Corporation
  • Pieris Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc
  • Sutro Biopharma, Inc.
  • Symphogen A/S
  • Tasly Pharmaceutical Group Co., Ltd.
  • Tesaro, Inc.
  • Theravectys SA
  • Tikcro Technologies, Ltd.
  • Vyriad
  • Xencor, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/cvfm7k/programmed_cell

View source version on businesswire.com: http://www.businesswire.com/news/home/20161017005746/en/

Business Wire
www.businesswire.com

Last updated on: 17/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.